

## Recombinant Human VCAM-1/CD106 protein (His tag)

**Catalog No.** PKSH033448

**Note:** Centrifuge before opening to ensure complete recovery of vial contents.


### Description

<b>Synonyms</b>	Vascular Cell Adhesion Protein 1, V-CAM 1, VCAM-1, INCAM-100, CD106, VCAM1, L1CAM
<b>Species</b>	Human
<b>Expression Host</b>	HEK293 Cells
<b>Sequence</b>	Phe25-Glu698
<b>Accession</b>	P19320
<b>Calculated Molecular Weight</b>	75.3 kDa
<b>Observed molecular weight</b>	100 kDa
<b>Tag</b>	C-His
<b>Bioactivity</b>	Testing in progress

### Properties

<b>Purity</b>	> 95 % as determined by reducing SDS-PAGE.
<b>Endotoxin</b>	Please contact us for more information.
<b>Storage</b>	Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.
<b>Shipping</b>	This product is provided as lyophilized powder which is shipped with ice packs.
<b>Formulation</b>	Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Please refer to the specific buffer information in the printed manual.
<b>Reconstitution</b>	Please refer to the printed manual for detailed information.

### Data



> 95 % as determined by reducing SDS-PAGE.

### Background

VCAM-1 is a single-pass type I membrane protein, contains 7 Ig-like C2-type domains. It is an endothelial ligand for very

### For Research Use Only

late antigen-4 (VLA-4) and  $\alpha 4 \beta 7$  integrin expressed on leukocytes, and thus mediates leukocyte-endothelial cell adhesion and signal transduction. VCAM-1 expression is induced on endothelial cells during inflammatory bowel disease, atherosclerosis, allograft rejection, infection, and asthmatic responses. During these responses, VCAM-1 forms a scaffold for leukocyte migration. VCAM-1 also activates signals within endothelial cells resulting in the opening of an "endothelial cell gate" through which leukocytes migrate. VCAM-1 has been identified as a potential anti-inflammatory therapeutic target, the hypothesis being that reduced expression of VCAM-1 will slow the development of atherosclerosis. In addition, VCAM-1-activated signals in endothelial cells are regulated by cytokines indicating that it is important to consider both endothelial cell adhesion molecule expression and function during inflammatory processes.